The recent UK-US policy developments are reshaping global pharmaceutical investment and launch strategies, according to intelligence platform GlobalData. In December 2025, the UK announced a landmark pharmaceuticals agreement with the US, granting UK-made medicines and medical technologies tariff-free access to the US market for at least three years. Alongside this, the UK committed to a […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!